Denali Therapeutics Inc. (DNLI) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
the bull case· 3
+13.58%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26294
managers reporting a position in thirteen F filings
13fJun 30 '264
of the funds on file reporting a position in DNLI
n-portas of Jun 30 '26the bear case· 4
9.25%
of revenue from the largest disclosed customer, Royalty Pharma plc
10-Kfiled Feb 26 '267 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2628
managers whose positions together make up four fifths of the reported value
13fJun 30 '268 of 8
recent reports where the move came in under the options-implied range
earnings historyimplied vs realizedSides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 6 '26 report. Not a forecast, not advice.
Of the 6 companies Denali Therapeutics Inc. moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
DNLI (Denali Therapeutics Inc.) has 7 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
tall tick = annual report · 2 on record
295 managers report a position worth $4.0B between them, and 28 of them hold 80% of it.
High 20.55 at 7:15 am ET, low 19.93 at 10:00 am ET.
Denali Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)